The Fallacy Of The Corporate Memory Concept

Puzzle idea thinking iStock-1031459576

You’re a chief medical officer at a developing/emerging pharma company and are about to start a study involving neurodegenerative disease. When traditional CROs start bidding, they’ll tell you how much experience their organization has in this field, how successful they’ve been, and how many qualified people they have to help see your study through to completion. You and the CRO both know that when you hand your trial over to them, you’re expecting the study to go as they promised. How does that typically work out? Facts and figures on success rates and experience can give you a warm and fuzzy feeling, but the reality is that the concept of corporate memory when it comes to clinical studies is false.

The theory of Corporate Memory is easy to understand and agree with – the better you record and understand recurring actions the better you will perform those actions. Read why Capitalizing on corporate memory might work at an individual level but is nothing more than a myth and an empty promise in the complex changing world of drug clinical studies.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: